---
title: Pre-surgical Evaluation for the Quantra System in Adult Patients Undergoing Cardiac Surgery
nct_id: NCT03931031
overall_status: COMPLETED
sponsor: HemoSonics LLC
study_type: OBSERVATIONAL
primary_condition: Blood Loss, Surgical
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03931031.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03931031"
ct_last_update_post_date: 2020-07-01
last_seen_at: "2026-05-12T06:24:33.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Pre-surgical Evaluation for the Quantra System in Adult Patients Undergoing Cardiac Surgery

**NCT ID:** [NCT03931031](https://clinicaltrials.gov/study/NCT03931031)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** HemoSonics LLC
- **Conditions:** Blood Loss, Surgical
- **Start Date:** 2019-03-21
- **Completion Date:** 2020-06-27
- **CT.gov Last Update:** 2020-07-01

## Brief Summary

This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the QPlus Cartridge in patients taking anitplatelet medication that are scheduled to undergo cardiac surgery.

## Detailed Description

The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The Quantra QPlus Cartridge was developed to monitor hemostasis during major surgical procedures in adult patients. The cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed in parallel yielding six parameters that depict the functional status of a patient's coagulation system.

This single-site, prospective, observational study will evaluate the performance of the Quantra System as compared to standard coagulation tests and comparable measures determined using TEG in patients taking antiplatelet medication that are scheduled to undergo cardiac surgery.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Subject is scheduled for elective cardiac surgery utilizing cardiopulmonary bypass, including the placement of a ventricular assist device
* Subject was identified as taking antiplatelet medication, specifically a P2Y12 inhibitor such that a TEG Platelet Mapping test is prescribed prior to surgery to assess possible platelet inhibition
* Subject is ≥ 18 years
* Subject is willing to participate and he/she has signed a consent form

Exclusion Criteria:

* Subject is younger that 18 years
* Subject is unable to provide written informed consent
* Subject is incarcerated at the time of the study
* Subject is pregnant
* Subject is currently enrolled in a distinct study that might confound the results of the proposed study
* Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks.
```

## Arms

- **Cardiac Surgery Patients** — Patients taking antiplatelet medication who are scheduled for elective cardiac surgery.

## Interventions

- **Quantra System** (DIAGNOSTIC_TEST) — Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care

## Primary Outcomes

- **Comparison of Quantra Clot Time test results to TEG test results.** _(time frame: Prior to surgery (Baseline))_ — Coagulation function assessed by Quantra and TEG.
- **Comparison of Quantra Clot Stiffness test results to TEG test results.** _(time frame: Prior to surgery (Baseline))_ — Coagulation function assessed by Quantra and TEG.
- **Comparison of Quantra Clot Time and Clot Stiffness test results to TEG test results.** _(time frame: Post-bypass (10 to 20 minutes after protamine administration).)_ — Coagulation function assessed by Quantra and TEG.
- **Comparison of Quantra Clot Time test results to TEG test results.** _(time frame: Post-bypass (10 to 20 minutes after protamine administration).)_ — Coagulation function assessed by Quantra and TEG.
- **Comparison of Quantra Fibrinogen Contribution to Clot Stiffness test results to laboratory fibrinogen** _(time frame: Prior to surgery (Baseline))_ — Coagulation function assessed by Quantra and laboratory fibrinogen testing
- **Comparison of Quantra Fibrinogen Contribution to Clot Stiffness test results to laboratory fibrinogen** _(time frame: Post-bypass (10 to 20 minutes after protamine administration).)_ — Coagulation function assessed by Quantra and laboratory fibrinogen testing
- **Comparison of Quantra Platelet Contribution to Clot Stiffness test results to laboratory platelet count** _(time frame: Post-bypass (10 to 20 minutes after protamine administration).)_ — Coagulation function assessed by Quantra and laboratory fibrinogen testing
- **Comparison of Quantra Platelet Contribution to Clot Stiffness test results to laboratory platelet count** _(time frame: Prior to surgery (Baseline))_ — Coagulation function assessed by Quantra and platelet count

## Locations (1)

- Huntsville Hospital, Huntsville, Alabama, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.huntsville hospital|huntsville|alabama|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03931031.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03931031*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*